MANDARA phase 3 RCT Benralizumab vs Mepolizumab in relapsing/refractory EGPA receiving SOC. Non-inferiority met. Abstr#L14 #ACR23 @RheumNow https://t.co/UnpF3RDHMa https://t.co/076SeynJx3
Links:
14-11-2023
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
